Theravance Biopharma Unveils 2025 Financial Performance and Strategic Direction Theravance Biopharma reports strong financial results for 2025, driven by record sales of YUPELRI® and outlines plans for future growth. A significant restructuring is also underway.

Theravance Biopharma Unveils 2025 Financial Performance and Strategic Direction #Ireland #Dublin #Theravance_Biopharma #YUPELRI #CYPRESS_Study

Theravance Biopharma Faces Challenges as CYPRESS Study Falls Short of Goals Theravance Biopharma announced disappointing results from the Phase 3 CYPRESS study, leading to a strategic review and significant cost-cutting measures.

Theravance Biopharma Faces Challenges as CYPRESS Study Falls Short of Goals #None #Theravance_Biopharma #YUPELRI #CYPRESS_Study